Topline data from PORTOLA Phase 2a clinical trial evaluating zetomipzomib in patients with autoimmune hepatitis (AIH) expected in first half 2025 Cash, cash equivalents and marketable securities totaled $148 million as of September 30, 2024 Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a business update. "The team at Kezar has made great progress towards completing the double-blind portion of the PORTOLA trial as we prepare for a data release in first half of 2025

Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of one-for-ten (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 5:00 p.m. Eastern Time on October 29, 2024 (the "Effective Time"). The Company's common stock will begin trading on a post-split basis at the market open on October 30, 2024. The Reverse Stock Split is part of the Company's plan to regain compliance with the minimum bid price requirement of $1.00 per share required to

Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that its Board of Directors (the "Board") has unanimously rejected the previously disclosed unsolicited, non-binding proposal from Concentra Biosciences, LLC ("Concentra") to acquire all of the outstanding shares of common stock of Kezar for cash consideration of $1.10 per share, plus a contingent value right that represents the right to receive 80% of the net proceeds from any out-license or disposition of Kezar's development programs or intellectual property. After careful consideration and with the a

PORTOLA Phase 2a clinical trial in patients with autoimmune hepatitis (AIH) to continue without modification following review by Independent Data Monitoring Committee (IDMC); reiterating guidance of topline data in first half 2025 PALIZADE Phase 2b clinical trial in patients with active lupus nephritis (LN) will be discontinued; focusing resources on clinical development of zetomipzomib in AIH Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced key clinical development updates. The IDMC overseeing the PORTOLA Phase 2a clinical trial of zetomipzomib

Kezar Life Sciences, Inc. ("Kezar" or the "Company") (NASDAQ:KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated diseases, today announced that it has received an unsolicited, non-binding proposal from Concentra Biosciences, LLC ("Concentra"), a Delaware limited liability company, to acquire all of the outstanding shares of common stock of Kezar for cash consideration of $1.10 per share, plus a contingent value right that represents the right to receive 80% of the net proceeds from any out-license or disposition of Kezar's development programs or intellectual property. According to a Schedule 13D filed on October 8, 2024, w

Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated diseases, today announced that it was informed via teleconference with the U.S. Food and Drug Administration (FDA) that the zetomipzomib Investigational New Drug (IND) application for the treatment of lupus nephritis (LN) has been placed on clinical hold. This action follows Kezar's communication to the FDA that Kezar was voluntarily suspending enrollment and dosing in its Phase 2b PALIZADE clinical trial of zetomipzomib in patients with active LN at the recommendation of the trial's Independent Data Monitoring Committee (IDMC). The IDMC's

Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated diseases, today announced the voluntary cessation in enrollment of new patients and dosing of ongoing patients in the Phase 2b PALIZADE clinical trial, pending further evaluation. PALIZADE is a global, placebo-controlled, randomized, double-blind Phase 2b clinical trial evaluating the efficacy and safety of two dose levels of zetomipzomib in patients with active lupus nephritis (LN). Patients in the trial are randomly assigned (1:1:1) to receive 30 mg of zetomipzomib, 60 mg of zetomipzomib or placebo subcutaneously once weekly for 52 weeks,

Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September, 11, 2024 at 12:00 pm ET in New York, NY. A webcast of the presentation will be available on the "Events & Presentations" section of the Company's website at www.kezarlifesciences.com. Following the event, an archived webcast will be available on the Kezar website for 90 days. About Kezar Life Sciences Kezar Life Sciences

Enrollment completed in PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis; revising guidance of topline data to first half 2025 PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis currently enrolling; reiterating guidance of topline data in mid-2026 Enrollment stopped in the KZR-261 Phase 1 study in refractory solid tumors; focusing resources on zetomipzomib development programs Cash, cash equivalents and marketable securities totaled $164 million as of June 30, 2024 Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet ne

Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that the Compensation Committee of the company's Board of Directors granted one employee a nonqualified stock option to purchase 72,000 shares of its common stock with an exercise price of $0.55 per share, which is equal to the closing price of Kezar's common stock on July 8, 2024, the grant date of the award. The stock option was granted as an inducement award material to the individual entering into employment with Kezar, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Kezar Life Sciences (NASDAQ:KZR) with a Buy and lowers the price target from $20 to $7.

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Kezar Life Sciences (NASDAQ:KZR) with a Buy and maintains $20 price target.

Kezar Life Sciences (NASDAQ:KZR) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.33) by 9.09 percent. This is a 3.23 percent increase over losses of $(0.31) per share from the same period last year.

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Kezar Life Sciences (NASDAQ:KZR) with a Buy and maintains $20 price target.

Kezar Life Sciences (NASDAQ:KZR) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.38) by 15.79 percent. This is a 76 percent decrease over losses of $(0.25) per share from the same period last year.

Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (NASDAQ:KZR) announced today that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) approved Kezar's investigational new drug (IND) application for initiation of the Phase 2b PALIZADE trial in China of zetomipzomib in patients with lupus nephritis (LN). Zetomipzomib is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. Everest will join Kezar and enroll patients in China as part of the ongoing PALIZADE trial, a global, placebo-controlled Phase 2b clinical trial evaluating the efficacy and safety of two d

The lithium market is facing persistent turmoil as spot prices have continuously declined for more than a year. Supply shortages and speculation caused a lithium bubble in 2022, with spot prices reaching CNY 600,000 ($84,400)/ton. However, increased production and subdued Chinese demand caused the bubble to burst, with prices returning below CNY 100,000 ($14,000)/ton — levels not seen since July 2021. Yet, the supply pressures are persisting. Chile, boasting the world’s largest reserves of lithium, is gearing up to open new extraction areas. Bloomberg reported major players in the global battery supply chain, including Tianqi Lithium, LG Energy Solution, and French miner Eramet ha

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Kezar Life Sciences (NASDAQ:KZR) with a Buy and maintains $20 price target.

Analysts have provided the following ratings for Kezar Life Sciences (NASDAQ:KZR) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 0 1 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 1 0 0 2M Ago 1 0 0 0 0 3M Ago 1 0 0 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, Kezar Life Sciences has an average price target of $15.5 with a high of $20.00 and a low of $2.00. Below is a summary of how these 4 analysts rated Kezar Life Sciences over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more neg

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Kezar Life Sciences (NASDAQ:KZR) with a Buy and maintains $20 price target.

Wells Fargo downgraded Kezar Life Sciences from Overweight to Equal Weight and set a new price target of $4.00

William Blair downgraded Kezar Life Sciences from Outperform to Mkt Perform

Wells Fargo initiated coverage of Kezar Life Sciences with a rating of Overweight and set a new price target of $19.00

HC Wainwright & Co. reiterated coverage of Kezar Life Sciences with a rating of Buy and set a new price target of $20.00 from $12.00 previously

JonesTrading initiated coverage of Kezar Life Sciences with a rating of Buy and set a new price target of $14.00

HC Wainwright resumed coverage of Kezar Life Sciences with a rating of Buy and set a new price target of $12.00

Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that its Board of Directors (the "Board") has unanimously rejected the previously disclosed unsolicited, non-binding proposal from Concentra Biosciences, LLC ("Concentra") to acquire all of the outstanding shares of common stock of Kezar for cash consideration of $1.10 per share, plus a contingent value right that represents the right to receive 80% of the net proceeds from any out-license or disposition of Kezar's development programs or intellectual property. After careful consideration and with the a

Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Company will pull forward its virtual Research and Development (R&D) Day to Wednesday, March 15, 2023 at 4:30 pm ET/1:30 pm PT. "The goal of Kezar's R&D Day is to set expectations for 2023, provide updates on our two clinical assets, and highlight the productivity from our Discovery team. We are progressing more quickly than planned with initiating PALIZADE, our next study of zetomipzomib for the treatment of lupus nephritis, and look forward to sharing the details," said John Fowler, Kezar's

Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it will host a virtual Research and Development (R&D) Day on Wednesday, March 22, 2023 at 4:30 pm ET/1:30 pm PT. Kezar's R&D Day will provide an extensive overview of the Company's pipeline, reviewing next steps on zetomipzomib, including the trial design for the Phase 2b portion of the lupus nephritis development program, as well as on its Protein Secretion Inhibition platform. The event will also highlight the recently announced autoimmune hepatitis (AIH) PORTOLA study, including a presentation

11 of 17 patients (64.7%) achieved an overall renal response of 50% or greater reduction in urine protein to creatinine ratio (UPCR) at 6 months 6 of 17 patients (35.2%) achieved a complete renal response, including a UPCR of 0.5 or less at 6 months Zetomipzomib continues to demonstrate a favorable safety and tolerability profile for administration over the 6-month treatment period Improvement seen in exploratory measures of extra-renal disease activity associated with systemic lupus erythematosus (SLE) in patients who completed treatment Company-hosted conference call and webcast to be held today at 4:30 p.m. ET Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage bi

KZR-616 demonstrates clinically meaningful benefit in patients with lupus nephritis, with 4 out of 5 patients achieving either a partial or complete renal response at end of treatment KZR-616 maintained a favorable safety and tolerability profile over the six-month treatment period Company-hosted investor and analyst conference call and webcast with guest investigator to be held today at 4:30pm ET Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported interim results from the Phase 2 portion of its MISSION clinical trial evaluating KZR-616, a first-i